Publications

5803 Results

Bortezomib + gemcitabine (Gem)/carboplatin (Carbo) results in encouraging survival in advanced non-small cell lung cancer (NSCLC): results of a phase II Southwest Oncology Group (SWOG) trial (S0339)

Authors
AM Davies;J McCoy;PN Lara;PH Gumerlock;J Crowley;DR Gandara
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#7017
Year
2006
Research Committee(s)
Lung
Study Number(s)
S0339

Phase II study of Erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST)

Authors
KH Albritton;C Rankin;CM Coffin;N Ratner;GT Budd;SM Schuetze;RL Randall;JE DeClue;EC Borden
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#9518
Year
2006
Research Committee(s)
Sarcoma
Study Number(s)
S0330

Rtog 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-fu vs. gemcitabine (G) for resected pancreatic adenocarcinoma

Authors
WF Regine;KW Winter;R Abrams;H Safran;JP Hoffman;A Konski;AB Benson;JS Macdonald;CG Willett;TA Rich
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#4007
Year
2006
Research Committee(s)
Gastrointestinal
Study Number(s)
R9704

Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimes for metastatic or locally advanced, unresectable disease: a Southwest Oncology Group study.

Authors
RP Whitehead;S McCoy;IS Wollner;L Wong;WG Harker;CD Blanke
Journal / Conference
ASCO 2006 Gastrointestinal Cancers Symposium #255
Year
2006
Research Committee(s)
Gastrointestinal
Study Number(s)
S0336

Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: a Southwest Oncology Group study

Authors
RP Whitehead;S McCoy;IS Wollner;L Wong;WG Harker;PM Hoff;PJ Gold;KG Billingsley;CD Blanke
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#3598
Year
2006
Research Committee(s)
Gastrointestinal
Study Number(s)
S0336

Markers of folate metabolism in pancreatic cancer: thymidylate synthase, thymidine phosphorylase, and MTHFR. results from the RTOG 9704 prospective randomized adjuvant treatment trial

Authors
JJ Farrell;K Winter;M Van Rijnsoever;W Regine;R Abrams;H Safran;J Macdonald;AB Benson;C Willett;H Elsaleh
Journal / Conference
ASCO 2006 Gastrointestinal Cancers Symposium #144
Year
2006
Research Committee(s)
Gastrointestinal
Study Number(s)
R9704

Absolute PSA value after androgen deprivation (AD) is a strong independent predictor of survival in new metastatic (D2) prostate cancer (PCa): Data from Soutwest Oncology Group trial 9346 (INT-0162)

Authors
M Hussain;C Tangen;P Schellhammer;ED Crawford;C Higano;G Wilding;A Akdas;EJ Small;B Donnelly;D Raghavan
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#4517
Year
2006
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-9346

Association of erectile dysfunction and subsequent cardiovascular disease

Authors
IM Thompson Jr;J Probstfield;C Tangen;P Goodman;C Moinpour;CA Coltman Jr
Journal / Conference
Proc of the AUA, Journal of Urology 175(4) Suppl:429 (#1333)
Year
2006
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

Prognostic value of hemoglobin change after initiation of androgen deprivations therapy for newly diagnosed metastatic prostate cancer: a multivariate analysis of SWOG 8894

Authors
TM Beer;BH Goldman;CM Tangen;LB Bland;M Hussain;TG DeLoughery;ED Crawford
Journal / Conference
Proc of the AUA, Journal of Urology 175(4) Suppl:385-386, (#1197)
Year
2006
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8894 (INT-0105) (EST-2889)

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321

Authors
B Barlogie;RA Kyle;KC Anderson;PR Greipp;HM Lazarus;DD Hurd;J McCoy;DF Moore Jr;SR Dakhil;KS Lanier;RA Chapman;JN Cromer;SE Salmon;B Durie;JJ Crowley
Journal / Conference
Journal of Clinical Oncology 24(6):929-936
Year
2006
Research Committee(s)
Myeloma
Study Number(s)
SWOG-9321